Repros asks FDA to lift clinical hold on Proellex
This article was originally published in Scrip
Repros Therapeutics has asked the US FDA to lift the clinical hold on the development of its lead product, Proellex (telapristone acetate, CDB-4124), after conducting analysis which it believes shows the drug has an acceptable safety profile.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.